Stoke Therapeutics (STOK) Cash from Operations Growth (1y) (2019 - 2026)
Stoke Therapeutics (STOK) Cash from Operations Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | Stoke Therapeutics | 1.90 Bn | 1.56 Bn | - | -145.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -145.96% |
| Dec 31, 2025 | -31.31% |
| Sep 30, 2025 | -40.49% |
| Jun 30, 2025 | -45.46% |
| Mar 31, 2025 | 636.62% |
| Dec 31, 2024 | -12.32% |
| Sep 30, 2024 | -25.22% |
| Jun 30, 2024 | 19.83% |
| Mar 31, 2024 | -15.03% |
| Dec 31, 2023 | 7.71% |
| Sep 30, 2023 | 21.74% |
| Jun 30, 2023 | -9.39% |
| Mar 31, 2023 | -165.73% |
| Dec 31, 2022 | -37.61% |
| Sep 30, 2022 | -50.22% |
| Jun 30, 2022 | -25.88% |
| Mar 31, 2022 | 261.36% |
| Dec 31, 2021 | -48.73% |
| Sep 30, 2021 | -35.03% |
| Jun 30, 2021 | -64.12% |